Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial
Shionogi & Co., Ltd. has announced that cefiderocol (S-649266), a novel siderophore cephalosporin in late-stage development, met the FDA pre-specified primary endpoint for…
Read More...
Read More...
